GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Getein Biotech Inc (SHSE:603387) » Definitions » Beneish M-Score

Getein Biotech (SHSE:603387) Beneish M-Score : -2.61 (As of May. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Getein Biotech Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.61 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Getein Biotech's Beneish M-Score or its related term are showing as below:

SHSE:603387' s Beneish M-Score Range Over the Past 10 Years
Min: -2.61   Med: -1.82   Max: 1.59
Current: -2.61

During the past 12 years, the highest Beneish M-Score of Getein Biotech was 1.59. The lowest was -2.61. And the median was -1.82.


Getein Biotech Beneish M-Score Historical Data

The historical data trend for Getein Biotech's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Getein Biotech Beneish M-Score Chart

Getein Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.70 -1.60 -2.45 -1.93 -2.56

Getein Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.35 -2.33 -2.39 -2.56 -2.61

Competitive Comparison of Getein Biotech's Beneish M-Score

For the Medical Devices subindustry, Getein Biotech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Getein Biotech's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Getein Biotech's Beneish M-Score falls into.



Getein Biotech Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Getein Biotech for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1504+0.528 * 0.9652+0.404 * 1.4353+0.892 * 0.7988+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.3264+4.679 * -0.037642-0.327 * 1.0444
=-2.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥484 Mil.
Revenue was 321.583 + 368.2 + 297.605 + 319.041 = ¥1,306 Mil.
Gross Profit was 229.85 + 248.361 + 195.709 + 203.782 = ¥878 Mil.
Total Current Assets was ¥2,021 Mil.
Total Assets was ¥3,788 Mil.
Property, Plant and Equipment(Net PPE) was ¥723 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥366 Mil.
Total Current Liabilities was ¥912 Mil.
Long-Term Debt & Capital Lease Obligation was ¥4 Mil.
Net Income was 86.013 + 50.702 + 60.35 + 47.194 = ¥244 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 67.115 + 186.713 + 28.671 + 104.352 = ¥387 Mil.
Total Receivables was ¥527 Mil.
Revenue was 384.316 + 444.693 + 403.956 + 402.496 = ¥1,635 Mil.
Gross Profit was 275.245 + 247.41 + 283.376 + 254.451 = ¥1,060 Mil.
Total Current Assets was ¥2,413 Mil.
Total Assets was ¥3,672 Mil.
Property, Plant and Equipment(Net PPE) was ¥554 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥345 Mil.
Total Current Liabilities was ¥842 Mil.
Long-Term Debt & Capital Lease Obligation was ¥8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(483.883 / 1306.429) / (526.551 / 1635.461)
=0.370386 / 0.321959
=1.1504

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1060.482 / 1635.461) / (877.702 / 1306.429)
=0.64843 / 0.671833
=0.9652

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2021.269 + 722.751) / 3788.151) / (1 - (2412.795 + 554.005) / 3671.973)
=0.275631 / 0.192042
=1.4353

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1306.429 / 1635.461
=0.7988

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 554.005)) / (0 / (0 + 722.751))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(366.033 / 1306.429) / (345.455 / 1635.461)
=0.280178 / 0.211228
=1.3264

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.823 + 911.891) / 3788.151) / ((7.638 + 842.235) / 3671.973)
=0.241731 / 0.231449
=1.0444

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(244.259 - 0 - 386.851) / 3788.151
=-0.037642

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Getein Biotech has a M-score of -2.61 suggests that the company is unlikely to be a manipulator.


Getein Biotech Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Getein Biotech's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Getein Biotech (SHSE:603387) Business Description

Traded in Other Exchanges
N/A
Address
No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
Executives
Su En Kui Director
Yan Bin Director
Kong Ting Ting Director
Xu Xing De Director
Su En Ben Director

Getein Biotech (SHSE:603387) Headlines

No Headlines